Determinants of uraemic toxin removal

被引:11
作者
Clark, WR
Gao, DY
机构
[1] Baxter Healthcare Corp, Div Renal, Deerfield, IL 60015 USA
[2] Indiana Univ Sch Med, Div Nephrol, Indianapolis, IN USA
[3] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA
关键词
convection; diffusion; haemodialysis; peritoneal dialysis; solute;
D O I
10.1093/ndt/17.suppl_3.30
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
The inability to excrete a wide spectrum of toxins is one of the hallmarks of uraemia and is responsible for many of the signs and symptoms of this syndrome. Therefore, an understanding of the factors influencing uraemic toxin removal, during both the pre-dialysis and dialytic phases, is critically important. This review addresses many of these factors, which include the importance of preserved residual renal function and the effect of therapy frequency. In addition, specifically with respect to larger uraemic toxins, the importance of convection and treatment duration is discussed. All of these issues will be major considerations as new dialytic therapies for end-stage renal disease patients are developed and implemented.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 36 条
[1]   FAILURE OF A DAILY HEMOFILTRATION PROGRAM USING A HIGHLY PERMEABLE MEMBRANE TO RETURN BETA-2-MICROGLOBULIN CONCENTRATIONS TO NORMAL IN HEMODIALYSIS-PATIENTS [J].
CANAUD, B ;
ASSOUNGA, A ;
KERR, P ;
AZNAR, R ;
MION, C .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1992, 7 (09) :924-930
[2]  
Canaud B, 1985, Contrib Nephrol, V46, P184
[3]  
Casino FG, 1996, NEPHROL DIAL TRANSPL, V11, P1574
[4]   The excretion of urea in normal man and in subjects with glomerulonephritis [J].
Chasis, H ;
Smith, HW .
JOURNAL OF CLINICAL INVESTIGATION, 1938, 17 (03) :347-358
[5]  
Churchill DN, 1996, J AM SOC NEPHROL, V7, P198
[6]  
Clark WR, 1999, J AM SOC NEPHROL, V10, P601
[7]  
Clark WR, 2002, J AM SOC NEPHROL, V13, pS41
[8]   Renal versus continuous versus intermittent therapies for removal of uremic toxins [J].
Clark, WR ;
Henderson, LW .
KIDNEY INTERNATIONAL, 2001, 59 :S298-S303
[9]   Serum immunoreactive leptin concentrations in normal-weight and obese humans [J].
Considine, RV ;
Sinha, MK ;
Heiman, ML ;
Kriauciunas, A ;
Stephens, TW ;
Nyce, MR ;
Ohannesian, JP ;
Marco, CC ;
McKee, LJ ;
Bauer, TL ;
Caro, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :292-295
[10]  
DAUGIRDAS JT, 1995, ASAIO J, V41, pM719, DOI 10.1097/00002480-199507000-00107